Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 12:00 AM
Ignite Modification Date: 2025-12-25 @ 12:00 AM
NCT ID: NCT00211458
Eligibility Criteria: Inclusion Criteria: 1. Clinical diagnosis of patients that previously had a failure of treatment with photodynamic therapy using Visudyne. 2. Patients must be at least 50 years of age. 3. Visual acuity of 20/30 to 20/320 in study eye on the Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity chart 4. Visual acuity of 20/800 or better in fellow eye on the ETDRS visual acuity chart Exclusion Criteria: 1. Patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions. 2. Patients who have undergone intraocular surgery within the last 2 months. 3. Patient participating in any other investigational drug study. 4. Use of an investigational drug or treatment related or unrelated to their condition within 30 days prior to receipt of study medication. 5. Inability to obtain photographs to document choroidal neovascularization (CNV) (including difficulty with venous access). 6. Patient with significant liver disease or uremia. 7. Patient with known adverse reaction to fluorescein and indocyanine green or iodine. 8. Patient has a history of any medical condition which would preclude scheduled visits or completion of study 9. Patient has had insertion of scleral buckle in the study eye 10. Patient has received radiation treatment 11. Patient is on anticoagulant therapy with the exception of aspirin 12. Patient is pregnant or nursing.
Sex: ALL
Minimum Age: 50 Years
Study: NCT00211458
Study Brief:
Protocol Section: NCT00211458